Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

ExpreS2ion: Workforce cut from 21 to five, December and Q1 2027 read-outs confirmed

EXPRS2Analyst Comment2026-11-20 06:35
Michael FriisHead of Equities

Summary

  • ExpreS2ion will reduce its workforce from 21 to five during 2027, cutting operating costs by approximately SEK 23m in 2027 and SEK 30m annually from 2028.
  • The company says the restructuring does not fund operations beyond the Phase I primary read-out. Additional financing and partnering remain necessary to initiate Phase II.
  • At the 5 October 2026 cut-off, 12 of 13 evaluable patients showed anti-HER2 responses, with no related serious adverse events. The company says these preliminary findings do not establish clinical benefit.
  • The company expects results from three translational studies in December 2026 and the Phase I primary read-out in Q1 2027. The analyst says platform and contract-services growth now depends on uncertain partnerships.

This content is generated by AI. You can give feedback on it in the Inderes forum.

ExpreS2ion announced after market close on 19 November that its Board of Directors has resolved to implement a restructuring, including a reduction in workforce, to lower operating costs and prioritise the development and partnering of ES2B-C001, its lead HER2-targeted active immunotherapy. The number of employees will be reduced from 21 to five during 2027.

Financial impact. Compared with the previous plan, operating costs are expected to be reduced by approximately SEK 23m in 2027, as the measures take effect during the year, and by approximately SEK 30m annually from 2028, once the restructuring is fully implemented in the second half of 2027. The Company states operating costs of SEK 56.5m for the full year 2025 and SEK 57.4m for the first nine months of 2026. Restructuring costs, mainly pay during notice periods and severance, are estimated at up to approximately SEK 5m and are expected to be charged largely to Q4 2026. Cash and cash equivalents amounted to SEK 35.8m on 31 October 2026, before settlement of existing liabilities.

Financing. The Company states that the restructuring does not by itself finance operations beyond the Phase I primary read-out, and that the Board is evaluating financing alternatives to fund ongoing working capital needs and the partnering process that follows the read-out. The Company adds that there is no guarantee that such financing can be obtained on acceptable terms, and that the measures do not remove the need for additional financing and partnering to initiate Phase II.

ES2B-C001 and milestones. All 19 patients have been enrolled and started treatment in the Phase I trial in advanced HER2-positive or HER2-low breast cancer. At the 5 October 2026 data cut-off, anti-HER2 antibody responses had been observed in 12 of 13 evaluable patients, with no dose-limiting toxicities and no serious adverse events assessed as related to ES2B-C001, observations the Company describes as preliminary and not establishing clinical benefit. Results from three translational studies of patient sera are expected in December 2026, the last patient’s last visit in the five-dose priming phase is expected at the end of December 2026, and the primary read-out is to be announced in Q1 2027. Phase II initiation remains targeted for the second half of 2027, subject to financing and partnering, Phase I data, regulatory interactions and final protocol development, with planning focused on evaluating ES2B-C001 alongside standard of care in a first-line setting.

Partnered programmes and platform. The malaria programmes continue as partner-led activities, with RH5.1 and R78C covered by the licensing agreement with Serum Institute of India from November 2025. On influenza, the INDIGO consortium concluded in Q1 2026 and no further work is planned without new external funding, while participation in the MucoVax collaboration will be discussed directly with the partners, including any required handover and outstanding grant obligations. The EU-funded VICI-Disease consortium continues towards clinical initiation of a Nipah vaccine during 2027. ExpreS2ion is pursuing strategic partnerships for the ExpreS2 platform and related contract services, will no longer prioritise expansion of its standalone CRO business, and states that the outcome and timing of these discussions remain uncertain.

Management and Board. The management team is unchanged, with CEO Bent U. Frandsen, CSO Max Søgaard and CFO Keith Alexander leading the smaller organisation. Board member Karin Garre steps down at the end of the year as part of reducing her professional commitments, leaving a Board of Martin R. Jensen, Michel Baijot and Jakob Knudsen.

Our take. The restructuring concentrates internal resources on ES2B-C001 while the partnered malaria and Nipah programmes continue under their existing partners and consortia. On our calculation, the approximately SEK 30m annual saving is a little over half the 2025 operating cost base, which is a substantial reduction for a company of this size, and it is achieved without touching the clinical timetable: the December translational results and the Q1 2027 primary read-out both stand, and the leadership that has to carry them remains in place. The trade-off is that platform and contract services value now depends on finding a partner rather than on building the business internally, and the Company is explicit that the timing and outcome of those discussions remain uncertain. The open question is financing. A lower run rate lengthens the Company’s reach, but the Board states that the measures do not on their own fund operations beyond the primary read-out, and the financing alternatives are being evaluated now rather than after the data. In our view, the sequence of the next two events, the Phase I read-out and the terms on which the Company funds itself through the partnering process that follows, is what matters most from here.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotech Holding AB for a Digital IR/Corporate Visibility subscription agreement. Michael Friis, 06:35, 20/11-2026

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

Read more on company page